BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...

A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. BioMarin Pharmaceutical beat analysts’ revenue expectations by ...

BioMarin expects full-year earnings in the range of $4.20 to $4.40 per share, with revenue in the range of $3.1 billion to $3.2 billion. BioMarin shares have decreased slightly since the beginning ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...